BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.
Arcellx, a privately held clinical-stage biopharmaceutical company, announced the addition of Kate Aiken as Chief People Officer. Kate is an accomplished human resources business leader who brings more than 20 years of cross-industry experience, building and managing high caliber HR organizations and partnering with business leaders to support the growth of industry leading companies.
John Gustin Joins CSSi LifeSciences As Associate Director of Commercial Development. His role will involve managing clients’ projects, which include regulatory filings and commercial planning. Also, he will be connecting clients with strategic partners, such as investors or distributors. Internally, he will be building out CSSi’s project management processes to assist in the scaling of the company
Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, is a highly regarded medical and research professional in infectious diseases with over 25 years of industry experience
The Maryland Department of Commerce has appointed Margia Argüello as Sr. Business Development Manager, BioHealth and Life Sciences, Office of Strategic Industries and Entrepreneurship. She has been tasked with cultivating and coordinating opportunities to expand, retain, and attract biohealth and life sciences businesses in Maryland. This includes the development and implementation of programs and initiatives to address the needs of the industry, such as talent attraction and workforce development; capital investment activity expansion; as well as technology transfer and commercialization strategies. Margia will also be working closely with entrepreneurs, start-ups, and early-stage life sciences companies to navigate the resources available to them throughout the Maryland life sciences ecosystem.
The Office of the County Executive at Montgomery County, Maryland recently announced the appointment of Judy Costello as Special Projects Manager. As Special Projects Manager, Judy supports a wide range of business and economic development-related projects (i.e., business/large employer recruitment and retention, education and workforce, small business and innovation, climate change, and transportation). Her focus covers multiple industries within the County.
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule after serving for 6 years as the Senior Director of Chemistry at Abzena, a leading chemistry, biologics and antibody-drug conjugate (ADC) research organization.
Early Charm, a venture studio that converts science to business, today announced the hiring of Dan Keeley to lead Lankenau Ventures, a new joint venture with Early Charm that aims to accelerate development and commercialization of medical inventions conceived by frontline healthcare workers.
The Center for Breakthrough Medicines at Discovery Labs, an ecosystem accelerating the path to commercialization for cell and gene therapy companies, has appointed Matthew Snyder to the role of Associate Director, Engineering & Facilities. Mr. Snyder will be responsible for establishing the critical support services necessary for laboratory and manufacturing operations. These include setup of a comprehensive safety program; implementation of equipment tracking and maintenance and calibration management systems; interface coordination between site infrastructure utilities, building monitoring and process control systems; and technical engineering support for process operations and facility design.
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.
